WELLESLEY, Mass., Sept. 15 Xceed Molecular, a pioneer inthe development of cost-effective, easy-to-use gene-expression analysissystems, announced that Queen's University in Kingston, Ontario, Canada, isthe latest high-profile institution to implement Xceed's Ziplex System as acritical tool to advance its translational research. Harriet Feilotter, Ph.D.,FCCMG, of the University's Department of Pathology and Molecular Medicine, isthe principal investigator of a study that will use the Ziplex System tovalidate her team's gene expression signature to predict the clinical outcomesin follicular lymphoma.
The most common form of non-Hodgkin lymphoma, accounting for one in fourof all cases, follicular lymphoma is a slow-growing cancer that arises fromB-lymphocytes, a type of white blood cell, and mainly affects older adults --men and women in equal numbers. The mean age of diagnosis is between 50 and 60years of age and because its symptoms are subtle in its earliest stages, thedisease often can remain untreated for a long time before it becomessymptomatic. Although most patients have good outcomes and can live long andproductive lives, in a substantial subset of patients, the disease can take amore aggressive course, resulting in shorter survival times.
"The work that Dr. Feilotter and her team at Queen's University have beendoing to develop novel diagnostic and prognostic tools in cancer shows greatpromise, and we are excited to be a part of it," said Xceed President and CEO,David Deems. "Her follicular lymphoma research, which includes the use of botharchival and fresh frozen tissues as sources of samples, has implications farbeyond this particular research study. We look forward to a productivepartnership."
Said Dr. Feilotter, "Our previous research identified a number of geneswhose expression levels in primary follicular lymphoma were correlated with afive-year outcome. The Ziplex System will facilitate and streamline thecritical next phase of our research to validate the signature. Currently thereare no molecular diagnostic tools on the market that can predict which primarytumors will be aggressive. Having an easy way to accurately categorize anindividual patient's risk will help clinicians determine the treatment planthat is most likely to result in a positive health outcome."
The Ziplex System is rapidly becoming the standard platform for thenation's leading institutions performing translational research. Xceeddesigned the Ziplex System with turnkey functionality and significant advancesin automation, array format, fluidics, parallel sample processing, andanalytics to minimize complexity, user interaction, and variability betweenusers and sites.
About Xceed Molecular (http://www.XceedMolecular.com)
Xceed's vision is to advance molecular diagnostics by successfullytranslating novel multiplex tests into routine clinical practice and to createrobust diagnostic solutions to improve disease outcomes. Our products comprisethe Ziplex System for automated gene-expression analysis (available in the USand Canada for research use only), gene expression services, andpre-configured arrays -- Xpress Chips(TM). Xceed is also developingmultiplexed genomic tests for the Ziplex platform, both internally and withstrategic partners. Xceed's R&D and manufacturing are headquartered inToronto, Ontario, with executive offices in Wellesley, Massachusetts.
About Queen's University (http://www.queensu.ca)
Established by Royal Charter of Queen Victoria in 1841, Queen's Universitywas the earliest degree-granting institution in the united Province of Canada.Today, Queen's is one of Canada's leading universities, with an internationalreputation for scholarship, research, social purpose, spirit and diversity.The Department of Pathology and Molecular Medicine of Queen's University isaffiliated with the University Hospitals Kingston. I